Daniel Jelovcan
Daniel Jelovcan is an analyst at Zürcher Kantonalbank (ZKB), specializing in the medical technology sector. He provides insights into the performance of companies like Sonova, highlighting the challenges they face in the U.S. market, particularly regarding sales of hearing aids amidst economic uncertainties and budget cuts affecting government contracts.
Not in the pool (under ¢1).
Recent news mentions
Daniel Jelovcan, a Medtech expert at Zürcher Kantonalbank, is convinced of the products and developments that Sonova has recently launched.
Schweizer Aktien: Sonova braucht noch Zeit
Switzerland· 2025-12-07
Daniel Jelovcan, an analyst at ZKB, explains Sonova's market share performance in the VA sector.
Weckruf für Sonova: der Tesla-Moment im Hörgeräte-MarktSwitzerland· 2025-07-22
Daniel Jelovcan noted that Tecan needs fresh leadership and welcomed the CEO change.
Kommentar zu SGS, Barry Callebaut, Tecan, R&S und SPSSwitzerland· 2025-07-11
Daniel Jelovcan is an analyst at Zürcher Kantonalbank who observes Medacta since its IPO.
Der aufstrebende Implantate-Hersteller setzt rechtzeitig auf die USASwitzerland· 2025-04-21
Daniel Jelovcan, an analyst at Zürcher Kantonalbank, notes the decline in hearing aid sales in the US.
Medtech-Anleger brauchen GeduldSwitzerland· 2025-04-10
